GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241310870 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Kelsey E Huntington und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Brown University, Providence, RI 02903, USA. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3, Colorectal Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCRR NIH HHS, National Cancer Institute of the National Institutes of Health.
Abstract (Originalsprache)
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that has been implicated in numerous oncogenic processes. GSK-3 inhibitor elraglusib (9-ING-41) has shown promising preclinical and clinical antitumor activity across multiple tumor types. Despite promising early-phase clinical trial results, there have been limited efforts to characterize the potential immunomodulatory properties of elraglusib. We report that elraglusib promotes immune cell-mediated tumor cell killing of microsatellite stable colorectal cancer (CRC) cells. Mechanistically, elraglusib sensitized CRC cells to immune-mediated cytotoxicity and enhanced immune cell effector function. Using western blots, we found that elraglusib decreased CRC cell expression of NF-κB p65 and several survival proteins. Using microarrays, we discovered that elraglusib upregulated the expression of proapoptotic and antiproliferative genes and downregulated the expression of cell proliferation, cell cycle progression, metastasis, TGFβ signaling, and anti-apoptotic genes in CRC cells. Elraglusib reduced CRC cell production of immunosuppressive molecules such as VEGF, GDF-15, and sPD-L1. Elraglusib increased immune cell IFN-γ secretion, which upregulated CRC cell gasdermin B expression to potentially enhance pyroptosis. Elraglusib enhanced immune effector function resulting in augmented granzyme B, IFN-γ, TNF-α, and TRAIL production. Using a syngeneic, immunocompetent murine model of microsatellite stable CRC, we evaluated elraglusib as a single agent or combined with immune checkpoint blockade (anti-PD-1/L1) and observed improved survival in the elraglusib and anti-PD-L1 group. Murine responders had increased tumor-infiltrating T cells, augmented granzyme B expression, and fewer regulatory T cells. Murine responders had reduced immunosuppressive (VEGF, VEGFR2) and elevated immunostimulatory (GM-CSF, IL-12p70) cytokine plasma concentrations. To determine the clinical significance, we then utilized elraglusib-treated patient plasma samples and found that reduced VEGF and BAFF and elevated IL-1 beta, CCL22, and CCL4 concentrations correlated with improved survival. Using paired tumor biopsies, we found that tumor-infiltrating immune cells had a reduced expression of inhibitory immune checkpoints (VISTA, PD-1, PD-L2) and an elevated expression of T-cell activation markers (CTLA-4, OX40L) after elraglusib treatment. These results address a significant gap in knowledge concerning the immunomodulatory mechanisms of GSK-3 inhibitor elraglusib, provide a rationale for the clinical evaluation of elraglusib in combination with immune checkpoint blockade, and are expected to have an impact on additional tumor types, besides CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Brown University, Providence, RI 02903, USA.
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Brown University, Providence, RI 02903, USA.
- The Joint Program in Cancer Biology, Lifespan Health System, Brown University, Providence, RI 02903, USA.
- Legorreta Cancer Center, Brown University, Providence, RI 02903, USA.
- Pathobiology Graduate Program, Brown University, Providence, RI 02903, USA.
- Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
ORCID-Profile: Kelsey E Huntington, Praveen R Srinivasan, David Silverberg, Francis J Giles, Benedito A Carneiro, Wafik S El-Deiry
Förderung
- NCI NIH HHS
- NCRR NIH HHS
- National Cancer Institute of the National Institutes of Health
- Teymour Alireza P’98, P’00 Family Cancer Research Fund
- Mencoff Family University Professorship at Brown University
- National Center for Research Resources (NCRR)
- National Institutes of Health
Zitieren
APA
Huntington, K. E., Louie, A. D., Srinivasan, P. R., Schorl, C., Lu, S., Silverberg, D., Newhouse, D., Wu, Z., Zhou, L., Borden, B. A., Giles, F. J., Dooner, M., Carneiro, B. A., & El-Deiry, W. S. (2023). GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310870
Vancouver
Huntington KE, Louie AD, Srinivasan PR, Schorl C, Lu S, Silverberg D, et al. GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310870
BibTeX
@article{Huntington2023,
author = {Huntington, Kelsey E and Louie, Anna D and Srinivasan, Praveen R and Schorl, Christoph and Lu, Shaolei and Silverberg, David and Newhouse, Daniel and Wu, Zhijin and Zhou, Lanlan and Borden, Brittany A and Giles, Francis J and Dooner, Mark and Carneiro, Benedito A and El-Deiry, Wafik S},
title = {GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241310870}
}
EUVIMED